Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Anterior Chamber Migrationof a Dexamethasone Implant ina Patient with a Scleral-Fixated Ocular Lens

Skleral Fiksasyonlu Göz İçi Lensi Olan Bir Olguda İntravitreal Deksametazon İmplantının Ön Kamaraya Migrasyonu

Pages
191–194
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We discuss the risk factors, clinical course, and complications of migration of a dexamethasone implant into the anterior chamber and subsequent management options

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dexamethasone implant (Ozurdex® Allergan) is a biodegradable drug delivery system which is an effective treatment in cases of macular edema.
📊
Key Findings & Data:In this report we describe a case of anterior chamber migration of a dexamethasone implant in a 64-year-old woman with macular edema due to Irvine Gass Syndrome who previously underwent a scleral-fixated lens implantation.
💡
Conclusion & Impact:We discuss the risk factors, clinical course, and complications of migration of a dexamethasone implant into the anterior chamber and subsequent management options
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Dexamethasone implant (Ozurdex® Allergan) is a biodegradable drug delivery system which is an effective treatment in cases of macular edema. However, migration of the implant into the anterior chamber might occur as a rare complication. In this report we describe a case of anterior chamber migration of a dexamethasone implant in a 64-year-old woman with macular edema due to Irvine Gass Syndrome who previously underwent a scleral-fixated lens implantation. Two weeks after an uneventful intravitreal Ozurdex implantation, the patient presented with painless visual loss. Slit-lamp examination revealed the presence of corneal edema associated with the implant in the anterior chamber which was surgically removed. We discuss the risk factors, clinical course, and complications of migration of a dexamethasone implant into the anterior chamber and subsequent management options

Özet

Deksametazon implantı (Ozurdex®, Allergan); maküla ödemi tedavisinde etkili, indirgenebilir ilaç salınım sistemidir. İmplantın ön kamaraya migrasyonu nadir bir komplikasyon olarak görülebilir. Bu yazıda, öncesinde skleral fiksasyonlu göz içi lens implantasyonu yapılmış ve Irvine Gass sendromuna bağlı maküla ödemi gelişmiş olan 64 yaşında kadın olguda, deksametazon implantın ön kamaraya migrasyonu tanımlanmıştır. Sorunsuz olarak gerçekleştirilen Ozurdex implantasyonundan iki hafta sonra, olgu ağrısız görme kaybıyla başvurmuştur. Biyomikroskobik muayenede korneal ödemle birlikte ön kamarada implant varlığı görülmüş ve takiben implant cerrahi olarak çıkarılmıştır. Bu yazıda deksametazon implantının ön kamaraya migrasyonunda risk faktörleri, klinik bulgular ve komplikasyonlar ve tedavi seçenekleri tartışılmıştır

🔖

Cite This Article

ÖNER, A., YILDIRIM, Y., SİNİM, N. (2015). Anterior Chamber Migrationof a Dexamethasone Implant ina Patient with a Scleral-Fixated Ocular Lens. Retina-Vitreus, Cilt: 23 - Sayı: 0, 191–194. https://ajindex.com/articles/307895

References (12)

  1. Chiang A, Haller JA The dexamethasone drug delivery system: indica- tions and evidence Adv Ther 2011 May;28:351-66.
  2. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macu- lar edema Clin Ophthalmol 2011;5:139-46. Collet B. Management of ozurdex in the anterior chamber JAMA Oph- thalmol 2013;131:1651-2.
  3. Schmitz K, Maier M, Clemens CR, et al; German Retinal Vein Occlu- sion Group. Reliability and safety of intravitreal Ozurdex injections. The ZERO study Ophthalmologe 2014;111:44-52.
  4. Brynskov T, Laugesen CS, Halborg J, et al. Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants Clin Ophthalmol 2013;7:1171-4.
  5. Dutra Medeiros M, Navarro R, Garcia-Arumí J, et al. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome Invest Ophthalmol Vis Sci Meyer LM, Schönfeld CL. Cystoid macular edema aftercomplicated cat- aract surgery resolved by an Intravitreal Dexamethasone 0.7-mg Im- plant. Case Rep Ophthalmol 2011;2:319-22.
  6. Laplace O, Rodallec T, Akesbi J, et al. Anterior chamber migration of a dexamethasone implant in a pseudophakic patient with a scleral-fixat- ed posterior chamber intraocular lens. J Fr Ophtalmol 2013;36:59-61.
  7. Kishore SA, Schaal S. Management of anterior chamber dislocation of dexamethasone implant. Ocul Immunol Inflamm 2013;21:90-1. Malclès A, Janin-Manificat H, Yhuel Y, Russo Aet al. Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseu- dophakic eyes: report of three cases. J Fr Ophtalmol 2013;36:362-7.
  8. Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravit- real implant (Ozurdex) migrated into the anterior chamber. Int Oph- thalmol 2012;32:583-4. Pardo-López D, Francés-Muñoz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol 2012;250:1703-4.
  9. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infec 2012;2:1-5.
  10. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and manage- ment strategies. Ophthalmology 2014;121:67-71.
  11. Eadie JA, Lesser R, Capone A Jr. Migration of Ozurdex implant into the anterior chamber. Retin Cases Brief Rep 2012;6:269-70.
  12. Carlos Mateo, Micol Alkabes, Anniken Bure´s-Jelstrup. Sc